President Obama: What You Need to Know

With today's inauguration, Barack Obama has become the 44th President of the United States.

(Photo Gallery: Obama Takes Office, Full Text: President Barack Obama's Inaugural Address)

Now, with Obama in the White House, how much do you really know about investing over the next 100 days -- and even the over next four years?

The following are key insights from TheStreet.com.

Biotech and Health Care

Obama Will Boost Biotech (Video)

Rosanne Ott, portfolio manager for the four star Alger Health Sciences Fund, says health care stocks will benefit during President Obama's first 100 days in office, especially generic drug-makers Teva (TEVA Quote) and Mylan (MYL Quote).

Related videos: TheStreet.com BioTalk: Obama and Health Care Reform and Obama Won't Obliterate Drug Stocks

From For Biotech Stocks, '09 May Be Touch and Go:

Investors will be watching closely for details of Obama's health-care reform agenda and how quickly any changes get enacted. Broader health-care coverage has the potential to increase prescription drug use, but higher volumes may be offset by government-negotiated (read: lower) drug pricing.

Biotech companies tend to focus on drugs that treat serious or fatal diseases, which may shelter them from some of the efforts to lower drug prices. However, the escalating cost of cancer medicines could render the companies that make them vulnerable.

Biogenerics, or low-priced copycat versions of biologic drugs, will also be coming to the U.S. market as soon as Congress and the Food and Drug Administration finalize a regulatory pathway.

There's already some evidence that American consumers are cutting back on prescription drug spending because of the recession. Clearly, that's not encouraging for drugmakers if the trend continues.

Again, biotech companies may be better positioned to weather a downturn in drug spending since many of the drugs they sell are designed to treat serious or fatal diseases. An HIV-positive person, for instance, is not likely to cut back on his HIV drugs from Gilead (GILD Quote). Likewise, a multiple sclerosis patient will find a way to continue taking Biogen Idec's (BIIB Quote) Avonex.

Read the full article.

Related articles: 'Mad Money Lightning Round': Allscripts Healthcare Works With Obama, Health Insurers-See-Universal-Opportunity and Health Care Reform and Your Health Stocks

Education

From Education Stocks on Obama's Honor Roll:

Education stocks have rallied over the past week, thanks in no small part to newly released details about Obama's proposed stimulus package. A positive earnings report from Apollo Group (APOL Quote) also helped the group advance, and analysts say that several important catalysts could push names like Apollo and Career Education (CECO Quote) even higher in the coming months.

Over the last year, education stocks have performed well even as the major stock averages have tumbled more than 35%. Corinthian Colleges (COCO Quote) has risen 27%, and Strayer Education (STRA Quote) has climbed 15%. Grand Canyon Education(LOPE Quote), public only since November, has jumped 70% in that time.

Even the sector's laggards have bettered the broader indices, with DeVry (DV Quote) slipping 9%, and Capella Education (CPLA Quote)losing 15% over the last year.

The group has already started 2009 with a bang after details of the incoming Obama administration's economic stimulus package were released by the House of Representatives.

Read the full article.